Reader TTS

ABSTRACT We analysed outcome in 206 consecutive male patients treated for metastatic non-seminomatous germ cell tumour (NSGCT) of testicular or extragonadal origin treated with the POMB/ACE

(cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) regimen after division into prognostic groups by commonly used clinical classification systems

and definitions of adverse prognosis. The adverse prognostic groups of all classification systems and definitions examined showed similar, but only moderate, sensitivity (71-81%) and

specificity (52-56%) in predicting death. A simple definition of poor prognosis based on raised initial levels of serum tumour markers alpha fetoprotein (aFP) and human chorionic

gonadotrophin (hCG) proved at least as useful (sensitivity 80%, specificity 55%) as other more complicated systems in predicting failure to achieve long-term survival. Comparison of survival

between ultra-high dose cisplatin-based combination chemotherapy and patients treated with POMB/ACE shows no advantage from this more toxic approach. This suggests that good results in

adverse prognosis patients can be achieved using conventional dose regimens administered intensively. Access through your institution Buy or subscribe This is a preview of subscription

content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue

Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL

ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS OUTCOMES OF RELAPSED CLINICAL STAGE I

VERSUS DE NOVO METASTATIC TESTICULAR CANCER PATIENTS: AN ANALYSIS OF THE IGCCCG UPDATE DATABASE Article Open access 30 September 2023 PATHOLOGICAL PREDICTORS OF METASTATIC DISEASE IN

TESTICULAR NON-SEMINOMATOUS GERM CELL TUMORS: WHICH TUMOR-NODE-METASTASIS STAGING SYSTEM? Article 15 December 2020 HIGH-DOSE CHEMOTHERAPY FOR RELAPSED TESTICULAR GERM CELL TUMOURS Article 07

December 2022 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Medical Oncology, Charing Cross Hospital, London, UK RN Hitchins Authors * RN Hitchins View author publications You

can also search for this author inPubMed Google Scholar * ES Newlands View author publications You can also search for this author inPubMed Google Scholar * DB Smith View author

publications You can also search for this author inPubMed Google Scholar * RHJ Begent View author publications You can also search for this author inPubMed Google Scholar * GJS Rustin View

author publications You can also search for this author inPubMed Google Scholar * KD Bagshawe View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND

PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hitchins, R., Newlands, E., Smith, D. _et al._ Long-term outcome in patients with germ cell tumours treated with

POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. _Br J Cancer_ 59, 236–242 (1989). https://doi.org/10.1038/bjc.1989.48 Download citation

* Issue Date: 01 February 1989 * DOI: https://doi.org/10.1038/bjc.1989.48 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link

Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative